Dimebon (latrepirdine) is a late-stage investigational clinical candidate for the treatment of two devastating neurodegenerative diseases, Alzheimer’s and Huntington diseases.

Overview

Dimebon, our lead product candidate, is an investigational compound currently in Phase 3 development for the treatment of Alzheimer’s disease and Huntington disease—progressive, devastating neurodegenerative diseases. Dimebon has a unique mechanism of action, distinct from currently available treatments. In preclinical studies, dimebon has been shown to protect brain cells from damage and enhance brain cell survival, potentially by stabilizing and improving mitochondrial function.

We are currently evaluating dimebon with our partner Pfizer Inc in clinical trials for both Alzheimer’s and Huntington diseases. In order to support a broad and differentiated label, we and Pfizer have expanded our Alzheimer’s Phase 3 clinical development program to include the following trials:

• The Phase 3 CONNECTION trial in patients with mild-to-moderate disease, for which enrollment is completed;
• The Phase 3 CONCERT study, which is currently enrolling patients with mild-to-moderate Alzheimer’s disease who are already being treated with donepezil, the leading Alzheimer’s disease medication worldwide;
• A placebo-controlled Phase 3 safety trial in patients on a variety of background anti-dementia medications being conducted to meet international safety database requirements, for which enrollment is completed;
• The Phase 3 CONSTELLATION trial, which is currently enrolling patients with moderate-to-severe Alzheimer’s disease and is evaluating as primary endpoints the effects of adding dimebon to memantine, a standard of care Alzheimer’s disease medicine, on cognition, memory and activities of daily living;
• The Phase 3 CONTACT study, which is currently enrolling patients with moderate-to-severe Alzheimer’s disease and is assessing as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil on neuropsychiatric symptoms and activities of daily living.

A Phase 3 trial in Huntington disease, known as HORIZON, is currently enrolling patients.